Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Irinotecan and Carboplatin (IC) Regimen for Small-Cell Lung Cancer and Non-Small-Cell Lung Cancer.

Literature DB >> 25477577

Irinotecan and Carboplatin (IC) Regimen for Small-Cell Lung Cancer and Non-Small-Cell Lung Cancer.

Matthew R Rutledge¹, J Aubrey Waddell¹, Dominic A Solimando¹.

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

Entities: Chemical Disease

Year: 2014 PMID： 25477577 PMCID： PMC4252228 DOI： 10.1310/hpj4907-603

Source DB: PubMed Journal: Hosp Pharm ISSN： 0018-5787

Keyword Cloud
References

49 in total

1. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Authors: Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff
Journal: J Clin Oncol Date: 2006-05-08 Impact factor: 44.544

Review 2. Antiemetics: American Society of Clinical Oncology clinical practice guideline update.

Authors: Ethan Basch; Ann Alexis Prestrud; Paul J Hesketh; Mark G Kris; Petra C Feyer; Mark R Somerfield; Maurice Chesney; Rebecca Anne Clark-Snow; Anne Marie Flaherty; Barbara Freundlich; Gary Morrow; Kamakshi V Rao; Rowena N Schwartz; Gary H Lyman
Journal: J Clin Oncol Date: 2011-09-26 Impact factor: 44.544

3. A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer.

Authors: A Schmittel; L Fischer von Weikersthal; M Sebastian; P Martus; K Schulze; P Hortig; M Reeb; E Thiel; U Keilholz
Journal: Ann Oncol Date: 2006-01-19 Impact factor: 32.976

4. Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer.

Authors: Nobuyuki Naka; Masaaki Kawahara; Kyoichi Okishio; Shigeto Hosoe; Mitsumasa Ogawara; Shinji Atagi; Yuuji Takemoto; Kiyonobu Ueno; Tomoya Kawaguchi; Tessei Tsuchiyama; Kiyoyuki Furuse
Journal: Lung Cancer Date: 2002-09 Impact factor: 5.705

5. Recommended guidelines for the treatment of cancer treatment-induced diarrhea.

Authors: Al B Benson; Jaffer A Ajani; Robert B Catalano; Constance Engelking; Steven M Kornblau; James A Martenson; Richard McCallum; Edith P Mitchell; Thomas M O'Dorisio; Everett E Vokes; Scott Wadler
Journal: J Clin Oncol Date: 2004-07-15 Impact factor: 44.544

9. Carboplatin dose calculation in lung cancer patients with low serum creatinine concentrations using CKD-EPI and Cockcroft-Gault with different weight descriptors.

Authors: Dieter Kaag
Journal: Lung Cancer Date: 2012-11-04 Impact factor: 5.705

10. Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer.

Authors: A Kinoshita; M Fukuda; H Soda; S Nagashima; M Fukuda; H Takatani; M Kuba; Y Nakamura; J Tsurutani; S Kohno; M Oka
Journal: Br J Cancer Date: 2006-05-08 Impact factor: 7.640